about
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapySmall-molecule Bcl-2 antagonists as targeted therapy in oncologyBH3 mimetics to improve cancer therapy; mechanisms and examplesTargeting Cell Survival Proteins for Cancer Cell DeathBcl-2 antagonists: a proof of concept for CLL therapySelective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemiaLoss of VOPP1 overexpression in squamous carcinoma cells induces apoptosis through oxidative cellular injury.Selective control of the apoptosis signaling network in heterogeneous cell populations.Straw blood cell count, growth, inhibition and comparison to apoptotic bodiesGambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins.Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cellsOxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.Why anti-Bcl-2 clinical trials fail: a solutionHigh-throughput screen for the chemical inhibitors of antiapoptotic bcl-2 family proteins by multiplex flow cytometry.Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice.High-throughput fluorescence polarization assay for chemical library screening against anti-apoptotic Bcl-2 family member Bfl-1.The polyamidoamine-mediated inhibition of bcl-2 by small hairpin RNA to induce apoptosis in human lens epithelial cells.Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathwaysApoptosis of human cholangiocarcinoma cells induced by ESC-3 from Crocodylus siamensis bileThe impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Sept4/ARTS is required for stem cell apoptosis and tumor suppression.Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cellsGossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAILVSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.Antiproliferative activity of plant extracts used against cancer in traditional medicineMcl-1 is up regulated by prenylated coumarin, umbelliprenin in jurkat cells.Cytotoxicity of methanol extracts of Elaeis guineensis on MCF-7 and Vero cell lines.c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.Chemotherapeutic approaches for targeting cell death pathways.Chemistry and biology of the caged Garcinia xanthones.Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosisCytotoxicity and hepatoprotective attributes of methanolic extract of Rumex vesicarius L.Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus Infection Induced Apoptosis and Autophagy in Thymi of Infected Piglets.Phytochemical capacity of Nitraria retusa leaves extracts inhibiting growth of melanoma cells and enhancing melanogenesis of B16F10 melanoma.Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsHematologic malignancies: newer strategies to counter the BCL-2 protein.Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells.Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities.
P2860
Q24635408-8E57DCB1-CF9C-4476-BBCB-3D2200C34C8EQ24646161-7EB1D12E-EC65-4217-A5CB-330AFAC4093FQ24655483-1A30B5F7-1972-443E-9446-CD495E4CBBDDQ26765447-04024378-EE6D-4400-B7A6-AF9E1485896EQ26823996-08756A23-4897-4283-8C1C-F46CEB98A95CQ27674083-3E0C61DC-5705-4C94-B24E-E70B02332FDDQ30453316-DE678FD0-D4A8-400C-8C64-0A620667B52CQ33288269-989CF989-A7A8-4CA1-8F95-E8BC018FA8B1Q33336245-99E5B6CB-3D6F-453B-90D4-687AE065DE80Q33345150-FDC552E9-C2B8-4E49-852A-0494E2EB24B3Q33381678-E4DCA3F6-2F77-4E1A-93F1-EE5A4EFFC1BCQ33689870-CBE83AEC-BBD7-4F7F-9975-97C0A59FF4E9Q33741142-E35459C4-FB96-461E-98BC-89ED9BCF11D4Q33758493-661E0538-89F8-4A73-A01A-A4BD345351FBQ33895708-0D100286-0A82-4027-9A75-692BF447BED4Q34091455-BDE08341-41F2-4A3F-BD40-007AEB730587Q34095986-D030E479-D25C-4DE2-911F-43FA6F225104Q34134038-F496C3B9-51A4-48F3-9D83-AC039F31FAC8Q34158470-F8196600-F142-4DD4-8052-D7F05FCE1454Q34169667-AD3F519A-135A-473B-BF3C-1278360D1C3DQ34195072-6D09DCDA-70EE-4B35-8782-208B38FBEABCQ34206039-C767B0B7-E462-4051-88F9-C7DFC7217C04Q34280097-6B324299-2160-4142-B46D-E794BE101B54Q34285051-80860A5D-9DF8-4FD7-9885-B43A380EAF9AQ34382986-35E4B0BE-FD6E-400E-8A5A-470B2FE414C7Q34410024-1807D391-3028-44F7-A94B-63E4911E53F3Q34516013-F239FD1E-738E-4FBB-BBB2-BF822B4E3C33Q34660373-7231CD58-9BD9-48A1-972A-B26FEB6D8774Q34667550-AF323382-BF4B-4272-A1A5-D0273BFCB31BQ35094229-CA5E7DBD-17D1-461C-9495-4123F1D7D5ADQ35129332-56FCA18A-4426-4749-ACAF-9D24A8AC4FCCQ35147669-7040E2EF-E908-4922-B223-A58158079605Q35258295-A741C4F7-E14B-4170-AF0E-4DE4CE5AC821Q35654016-095EF5C1-4B19-48C9-9E9A-4CA5A9ABA6C4Q35761622-BAC3AEE3-502D-44BF-9FE3-49FC96EC5DAEQ35859229-EBB2DAE7-040F-4372-A347-469C1A7AB4D5Q35975387-F12FDA40-8685-432C-9DF1-949208FF91AFQ35979110-AF5747AA-9D94-456E-89B8-DCD2DAF183EEQ36146021-7CD35552-4894-499F-8A97-036B1F7B1E8CQ36490192-BEBBC8CE-5E99-4CBC-8D11-27CAF8186E02
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Apoptosis-based therapies for hematologic malignancies.
@ast
Apoptosis-based therapies for hematologic malignancies.
@en
Apoptosis-based therapies for hematologic malignancies.
@nl
type
label
Apoptosis-based therapies for hematologic malignancies.
@ast
Apoptosis-based therapies for hematologic malignancies.
@en
Apoptosis-based therapies for hematologic malignancies.
@nl
prefLabel
Apoptosis-based therapies for hematologic malignancies.
@ast
Apoptosis-based therapies for hematologic malignancies.
@en
Apoptosis-based therapies for hematologic malignancies.
@nl
P1433
P1476
Apoptosis-based therapies for hematologic malignancies.
@en
P2093
John C Reed
Maurizio Pellecchia
P304
P356
10.1182/BLOOD-2004-07-2761
P407
P577
2005-03-29T00:00:00Z